Magali Q.
- Country
- France
- Department
- Radiation Therapy
Research Overview
- Phase I/II Study of Stereotactic Ablative Reirradiation with Metformin for Relapse in Previously Irradiated Prostate Bed (REPAIR GETUG P16)
- Phase II Randomized Trial of Stereotactic Body Radiation Therapy With or Without Durvalumab in Oligometastatic Hormone-Sensitive Prostate Cancer
- Evaluation of Darolutamide Combined with Stereotactic Body Radiation Therapy in Castration-Resistant Prostate Cancer with Oligometastases Detected by Functional Imaging
Data & Insights
Has run more than one trial at 46 of 187 partner sites.
Specializations
Advanced Prostate Cancer Management
The investigator specializes in treating various stages of prostate adenocarcinoma, with particular emphasis on hormone-sensitive and castration-resistant prostate cancer.
- Biochemically Recurrent Disease
- Hormone-Naïve Prostate Cancer
- Oligometastatic Disease
Their work integrates novel therapeutic approaches for managing prostate cancer progression and recurrence.
Innovative Treatment Combinations
The investigator focuses on combining androgen receptor inhibitors with various therapeutic modalities, including hormone therapy and radiation treatment.
- Darolutamide-Based Therapy
- Apalutamide Applications
- Stereotactic Radiation Approaches
Their research explores optimal treatment sequences for high-risk prostate cancer patients.
Advanced Imaging and Treatment Planning
The investigator utilizes next-generation imaging techniques for precise disease monitoring and treatment planning.
- PSMA PET/CT Implementation
- Functional Imaging Applications
- Treatment Response Assessment
Their expertise includes using advanced imaging for guiding personalized treatment decisions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.